Individualized Functional Connectivity Targeting in aiTBS for Depression
| 대상 질환 | Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Brigham and Women's Hospital |
| 상태 | 완료 |
| 참여자 수 | 40 명 |
| 중재(약물) | transcranial magnetic stimulation |
| 시작일 | 2023년 7월 15일 |
| 완료일 | 2025년 3월 17일 |
| 결과 공개일 | 2026년 7월 7일 |
요약
The goal of this clinical trial is to estimate the importance of neuroimaging in accelerated intermittent theta burst stimulation (aiTBS) for depression. Participants will receive aiTBS treatment, but they will not know if their treatment spot was found with neuroimaging or head measurements.
Montgomery-Åsberg Depression Rating Scale (MADRS)
| Connectivity-based Targeting | 35 Scores on scale |
|---|---|
| Scalp-based Targeting | 31 Scores on scale |
| Connectivity-based Targeting | 6 Scores on scale |
| Scalp-based Targeting | 11 Scores on scale |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital